





OCTOBER 2026
URUGUAY

Red Biotech UY Company Portfolio

Science, companies and collaboration opportunities.



01

Companies, Development and Financing

A network of Uruguayan startups spanning human therapeutics, diagnostics, bioproduction and animal health. Opportunities range from R&D to commercial businesses, through licensing, co-development, services and B2B supply.

12

startups in the portfolio

2–8

reported TRL range · 12/12

USD 18.24M

reported financing · 8/12

CATEGORY MIX		DEVELOPMENT STAGES			
● Human therapeutics	6	R&D	1	Preclinical validation	4
● Diagnostics & genomics	3	MVP	1	Clinical stage	2
● Bioproduction & biomaterials	2	Pre-commercial	2	Commercial	2
● Animal health	1				

REPORTED CAPITAL · USD MILLIONS

Eolo Pharma 7 · Xeptiva Therapeutics 5 · Ardan Pharma 1.62 · Nanogrow Biotech 1.4 · B4-RNA 1.4 · Locbio 0.9 · Polymera 0.67 · NanoProX 0.25.

Subtotal of available figures for 8 of 12 members; 4 do not report an amount. This is not the network's total capital and excludes open fundraising targets.

WHAT THE COMPANIES ARE LOOKING FOR

Capital & investors	9	Ardan Pharma · B4-RNA · Eolo Pharma · Guska · Locbio · Nanogrow · NanoProX · Polymera · Xeptiva
Scale-up, pilots & GMP	2	Polymera · Xeptiva
Pharma & clinical partners	9	Ardan Pharma · B4-RNA · Eolo Pharma · Eywa · Guska · Locbio · Nanogrow · NanoProX · Xeptiva
Customers, channels & expansion	3	Enteria · Eywa · GeneXa

Grouped from stated needs; categories overlap.



HUMAN THERAPEUTICS

oncology

immunotherapy

small molecule

KEY FACTS

Stage	Preclinical validation
TRL	4
Founded	2019
Model	Mixed
Team	2-10

TEAM



Maria Varela
CEO / co-founder



Marcelo Hill
CSO / co-founder



Pablo Opezzo
co-founder

CONTACT

ardan-pharma.com
mariavarela@ardan-pharma.com
Uruguay

RED BIOTECH UY

Ardan Pharma

An innovative immunotherapy for cancer treatment



THE PROBLEM

Many cancer patients do not respond to current treatments or develop resistance. Colorectal cancer is the third most frequently diagnosed cancer and the second leading cause of cancer death. Incidence before age 50 is rising; five-year relative survival in advanced disease is around 14%, reinforcing the need for new therapeutic approaches.

TECHNOLOGY

Ardan develops first-in-class small molecules that block TMEM176A/B to activate antitumor immunity and overcome resistance to checkpoint inhibitors. In several preclinical models, they controlled tumor growth and improved survival. Biological mechanisms published by the team underpin its intellectual property.

PRODUCT & MARKET

The model combines licensing and co-development with pharmaceutical companies able to run advanced clinical trials and commercialize the drug. Ardan is designing a Phase I trial in colorectal cancer resistant to immunotherapies; it identified genetic biomarkers to define eligibility and improve result specificity. Clinical proof of concept will be key to establishing partnerships.

WHAT WE ARE LOOKING FOR

Ardan seeks to complete its seed round to fund preclinical studies and advance the regulatory requirements for its clinical trial.



HUMAN THERAPEUTICS

metabolic

small molecule

KEY FACTS

Stage	Clinical stage
TRL	5
Founded	2019
Model	Licensing

TEAM



Pía Garat
CEO / co-founder



Carlos Escande
CSO



Carlos Batthyany
CMO

CONTACT

eolo-pharma.com
pgarat@eolo-pharma.com
Uruguay

RED BIOTECH UY

Eolo Pharma

A drug that activates fat burning by promoting energy expenditure, without suppressing appetite



THE PROBLEM

Obesity and related metabolic diseases affect millions of people worldwide. Many do not respond to or cannot tolerate current treatments, which focus on suppressing appetite, leaving an unmet need for therapies based on increasing the body's energy expenditure.

TECHNOLOGY

SANA (MVD1) is an oral small molecule derived from salicylate that, in preclinical models, increased energy expenditure through creatine-dependent thermogenesis rather than suppressing appetite. In 2025 Eolo became the first Uruguayan startup to complete a Phase I clinical study: a randomised, placebo-controlled Phase 1a/b trial in 41 volunteers showed good safety and tolerability up to 400 mg daily, with exploratory signals of weight reduction. The results were published in Nature Metabolism.

PRODUCT & MARKET

The lead asset is SANA/MVD1, an oral molecule for obesity positioned as an alternative or complement to GLP-1 agonists, though that differentiation still needs clinical validation. The business model is B2B: licensing or partnering with mid-size or large pharmaceutical companies for phase 3 and global commercialization, with a focus on the United States and Europe.

WHAT WE ARE LOOKING FOR

Eolo is seeking to close a funding round for its Phase 2 clinical trial, strengthen its team and expand into the United States and Europe, bringing in life-science specialist investors and a pharma partner for the stages ahead.



HUMAN THERAPEUTICS

oncolytic viruses

oncology

immunotherapy

applied AI

KEY FACTS

Stage	Preclinical validation
TRL	3
Founded	2024
Model	Licensing
Team	9

TEAM



Nicolás Tambucho
CEO



Gonzalo Moratorio
co-founder and Scientific Leader



Pilar Moreno
co-founder and Scientific Leader


CONTACT

guska.bio
ntambucho@guska.bio
Uruguay y España

RED BIOTECH UY

Guska

Programmable virotherapies for aggressive solid tumors: each tumor, its own vaccine



THE PROBLEM

Guska focuses on aggressive tumors with few options that change prognosis: glioblastoma, with around 15 months' survival and no major advances since 2005, and metastatic pancreatic cancer, with 8–11 months. These cold, immunosuppressive and resistant tumors are difficult to treat.

TECHNOLOGY

Guska reprograms RNA-virus genomes with safety switches to replicate selectively in tumor cells, destroy them and activate immunity while sparing healthy cells. It has two proprietary patented candidates with preliminary efficacy and safety in animal models. Its AI platform designs and prioritizes genomes before synthesis and validation at its laboratories in the Institut Pasteur de Montevideo.

PRODUCT & MARKET

A preclinical pipeline of oncolytic RNA virotherapies reprogrammed through synthetic biology, focusing on glioblastoma with parallel programs in seven cancer types. An AI platform for generating new viral candidates complements the pipeline.

WHAT WE ARE LOOKING FOR

Guska seeks specialist venture capital to advance toward early clinical trials and develop a precision-virotherapy hub using its AI platform. It aims to strengthen its team and network through specialists and pharmaceutical companies in the United States, Europe and Latin America.



HUMAN THERAPEUTICS

synthetic biology

oncology

cell therapy

applied AI

KEY FACTS

Stage	Therapeutic R&D; operating services
TRL · Platform	6
TRL · Therapeutics	2
Founded	2023
Model	Mixed
Team	6

TEAM



Felipe Trajtenberg
Founder and CEO



Dayana Benchoam
COO


CONTACT

locbio.com
dbenchoam@locbio.com
Montevideo, Uruguay

RED BIOTECH UY

Locbio

AI-designed biosensors that reprogram cells against cancer.



THE PROBLEM

Programming biology precisely requires fast, reliable detection of specific molecular signals. Current sensors are slow, poorly adaptable to new targets and rarely integrate more than one signal, limiting the development of better diagnostics and more precise, safer therapies.

TECHNOLOGY

GRIPT uses AI to design modular protein biosensors: one module recognizes the target molecule and another triggers a response, such as generating light or releasing a therapeutic molecule where needed. It draws on more than 17 years of research at the Institut Pasteur de Montevideo and was validated to detect drugs and proteins. Its patent is entering national phases and its results are approaching publication in a peer-reviewed scientific journal.

PRODUCT & MARKET

Locbio offers custom biosensor design and cell reprogramming for diagnostics, healthcare, industrial and biotechnology companies. In parallel, it uses its platform to develop a therapeutic bacterium for colorectal cancer and an enhanced CAR-T therapy for solid tumors.

WHAT WE ARE LOOKING FOR

Locbio seeks to close a seed round to accelerate commercialization of its platform and advance its therapeutic pipeline. It seeks partnerships with CAR-T companies to move toward clinical development and, separately, to bring its therapeutic bacterium to an MVP that enables progress toward preclinical studies.



HUMAN THERAPEUTICS

oncology

immunotherapy

antibodies

companion animals

KEY FACTS

Stage	Preclinical validation
TRL	5
Founded	2021
Model	Mixed
Team	20+

TEAM



Nicolás Galmarini
CEO / co-founder



Lucía Vanrell
co-founder and CSO

CONTACT

nanogrowbiotech.com


ngalmarini@nanogrowbiotech.com

Montevideo, Uruguay y Pamplona, España

RED BIOTECH UY

Nanogrow Biotech

Localized biological therapies based on nanoantibodies for immune-mediated diseases and cancer



THE PROBLEM

Monoclonal antibodies are highly effective treatments for immune-mediated diseases and cancer, but cost limits access and injectable administration can cause adverse effects. Nanogrow aims to broaden access through localized biological therapies.

TECHNOLOGY

Nanogrow develops small, stable camelid nanoantibodies for topical, oral, inhaled or intratumoral delivery, aiming to concentrate treatment and minimize systemic toxicity. Their stability enables formulations without a cold chain; they are produced in bacteria or yeast. Its proprietary platform integrates discovery, engineering, AI-assisted optimization and indication-specific formulation.

PRODUCT & MARKET

Nanogrow combines a proprietary pipeline in human oncology and immunology, a veterinary vertical, and co-development services with international pharmaceutical companies, under a B2B model that blends co-development, licensing and revenue-sharing. It operates from Montevideo and Pamplona, with an immediate commercial focus on the European pharmaceutical market and active participation in international investment and partnering forums.

WHAT WE ARE LOOKING FOR

Nanogrow is closing its seed round to advance its lead asset toward clinical development and expand its pharmaceutical market presence. It seeks pharma partnerships to advance programs in immune-mediated diseases through co-development and licensing, from preclinical validation to clinical development.

HUMAN THERAPEUTICS

oncology

nanotechnology

KEY FACTS


Stage	Preclinical validation
TRL	4
Founded	2025
Model	Licensing
Team	5

TEAM**Federico Kramer**
CEO and co-founder**Ivana Aguiar**
COO and co-founder**Isabel Galain**
CSO and co-founder**Camila Pérez**
CIO and co-founder**María Eugenia Pérez**
CRO and co-founder**CONTACT**

www.nanoprox.com
info@nanoprox.com
Uruguay

RED BIOTECH UY

NanoProX

Nanoparticles that enhance radiotherapy**THE PROBLEM**

Radiotherapy is used in more than half of cancer patients, but its precision still limits protection of healthy tissue. Adverse effects restrict treatment doses and affect quality of life. Current strategies also fail to adequately address hard-to-reach or metastatic tumors.

TECHNOLOGY

NanoProX develops bismuth sulfide radiosensitizing nanoparticles: nanoscale size helps them reach the tumor; the core locally amplifies radiation; a biocompatible coating supports stable circulation; and a targeting molecule increases selective accumulation. Given intravenously before radiotherapy, they aim to maximize tumor damage and reduce side effects using existing equipment.

PRODUCT & MARKET

NanoProX is at the preclinical stage and reports efficacy in in vivo lung cancer models. The technology has been developed for ten years at Universidad de la República, with collaboration from Universidade de São Paulo, and has a PCT patent application. Its model combines licensing or co-development with clinical oncology centers and pharmaceutical companies.

WHAT WE ARE LOOKING FOR

NanoProX is looking to bring on research institutions, clinical oncology centers, strategic investors, and pharmaceutical or medtech partners to support its preclinical and clinical validation.

B4 RNA

DIAGNOSTICS & GENOMICS

oncology

liquid biopsy

genomics

applied AI

KEY FACTS

Stage	Pre-commercial
TRL	5
Founded	2024
Model	Mixed
Team	7

TEAM



Carlos Palma
CEO



Juan Pablo Tosar
Founder and CSO


CONTACT

b4rna.com
cpalma@b4rna.com
Montevideo, Uruguay

RED BIOTECH UY

B4-RNA

Liquid biopsy that detects cancer early by repairing damaged RNA



THE PROBLEM

Cancer is often diagnosed too late. Conventional RNA liquid biopsy methods read molecules that fragment during sample preparation, losing information that could enable earlier, less invasive detection.

TECHNOLOGY

REJOIN-seq™ enzymatically repairs circulating transfer RNA that conventional methods fragment, then sequences it with next-generation technology. The method's biological basis was published in Proceedings of the National Academy of Sciences in 2023. It is protected by a patent family with inventors from the Institut Pasteur de Montevideo, Universidad de la República and Johns Hopkins University, and already includes an announced collaboration with Resolve Therapeutics for autoimmune diseases.

PRODUCT & MARKET

B4-RNA already offers a contract research service for laboratories, processing samples and delivering transfer RNA data. In parallel, it is developing a diagnostic product based on REJOIN-seq™, with a regulatory path planned as a laboratory-developed test (LDT) followed by PMA approval in the United States, its priority market.

WHAT WE ARE LOOKING FOR

B4-RNA is seeking to close a pre-Series A round to fund clinical validation and U.S. market entry, along with mentorship and visibility in diagnostics, reimbursement and clinical commercialization, plus alliances with pharma companies, sequencing providers and laboratories.

ENTERIN

DIAGNOSTICS & GENOMICS

microbiome

genomics

KEY FACTS

Stage	Commercial
TRL	6
Founded	2019
Model	Mixed

TEAM



Pia Campot
CEO, co-founder



Rodrigo Achigar
CSO, co-founder

FM

Felipe Machado
COO, co-founder

DS

Diego Saráchaga
CTO, co-founder

CONTACT

enteria.uy
pia@enteria.uy
Uruguay

RED BIOTECH UY

Enteria

Intestinal and vaginal microbiota sequencing, from kit to report



THE PROBLEM

Microbiota science is advancing, but physicians still need simple, reliable, clinically applicable tools to measure and interpret it. Latin America lacks regional infrastructure to translate scientific evidence into accessible, scalable diagnostics.

TECHNOLOGY

Enteria combines whole-metagenome sequencing, in-house bioinformatics, proprietary clinical databases and AI to produce clinically actionable reports. It analyzes bacteria, fungi and parasites using machine-learning models trained on local cohorts. Its logistics enable sample storage and transport at room temperature from Latin America to a centralized laboratory in Uruguay, without replicating infrastructure in each market.

PRODUCT & MARKET

A B2B clinical microbiota diagnostics platform for laboratories, clinics and physicians. Its turnkey service includes collection kits, transport, processing and customizable clinical reports through a digital platform, focusing on vaginal, intestinal and urinary microbiota. With a laboratory in Montevideo, it generates growing revenue and has a presence in Argentina, Colombia, Panama and Bolivia, expanding through clinics and laboratories.

WHAT WE ARE LOOKING FOR

Enteria seeks to accelerate regional expansion, broaden its diagnostic portfolio and strengthen its clinical databases. It aims to develop and validate predictive and AI models for specific clinical conditions and become a reference infrastructure for microbiota diagnostics in Latin America.

GeneXa®

DIAGNOSTICS & GENOMICS

genomics

agrifood

KEY FACTS

Stage	Commercial
TRL	8
Founded	2020
Model	B2B services
Team	2–10

TEAM



Andrés Pereira Conde
Director



Rosina Fossati
co-founder

CONTACT

genexa.com.uy
pereira@genexa.com.uy
Uruguay

RED BIOTECH UY

GeneXa

Accredited genetic lab serving livestock, agriculture and food



THE PROBLEM

The agricultural and food industry needs to accurately verify the genetic origin of livestock, the varietal identity of crops, and the authenticity of food, in order to prevent fraud, hereditary diseases, and errors in breeding and traceability programs.

TECHNOLOGY

GeneXa is the only Uruguayan laboratory specialised in molecular genetic analysis for the agricultural — animal and plant — and food sectors, with microarray genotyping, next-generation sequencing, species identification and molecular traceability. It holds ISO/IEC 17025:2017 accreditation (LE 044) from the Uruguayan Accreditation Body for bovine and equine DNA extraction and typing and for species detection in meat.

PRODUCT & MARKET

The model is B2B services: genetic analyses and custom assay development for farmers, veterinarians, breeding programmes, researchers and food companies. GeneXa operates commercially with more than 600 clients in Uruguay and the region, and runs a channel in Argentina through GenLab SF, which collects samples and routes the analyses to the Uruguayan laboratory.

WHAT WE ARE LOOKING FOR

GeneXa is looking to grow revenue by widening its client base in Uruguay and the region, and for support in consolidating a tax framework that favours biotech research and development, with greater clarity on the IRAE and IRNR exemptions that apply to this activity.



BIOPRODUCTION & BIOMATERIALS

synthetic biology

manufacturing

mental health

KEY FACTS

Stage	Pre-commercial
TRL	5
Founded	2023
Model	B2B supply
Team	13

TEAM



Victoria Costa Paz
Founder and CEO



Pablo Salaverria
Partner and COO

CONTACT

www.eywa.bio
pablo@eywa.bio
Montevideo, Uruguay

RED BIOTECH UY

Eywa

A new model for mental health: from molecule to patient



THE PROBLEM

Mental health needs innovation in both molecules and how therapy is delivered. Psychedelics have a growing evidence base, but their development requires advances in the drug, patient support and public discussion of mental health.

TECHNOLOGY

Eywa integrates three layers: biosynthetic manufacturing of pharmaceutical-grade psilocybin; Waello, a mental-health tracking and monitoring app; and Eywa Academy, an education platform. Using an *E. coli* strain licensed from Miami University, Ohio, it developed scale-up, downstream processing and pharmaceutical purification in-house. The license was renewed and remains valid until patent expiry.

PRODUCT & MARKET

The model combines B2B supply of pharmaceutical-grade molecules to pharmaceutical companies and mental-health research centers with a B2B2C model for Waello, reaching patients and individuals through clinics and employers.

WHAT WE ARE LOOKING FOR

Eywa seeks partners to develop its business and the future of mental health: pharmaceutical companies, clinical professionals and employers that see their teams' mental health as a key performance factor.

POLYMERA

BIOPRODUCTION & BIOMATERIALS

biomaterials

sustainability

extremophiles

KEY FACTS

Stage	MVP
TRL	4
Founded	2024
Model	Mixed
Team	2-10

TEAM



Eloisa Arrarte
co-founder and CEO



Carmina Reyes Plascencia
co-founder and COO



Humberto González
co-founder and CSO

CONTACT

polymera.bio
earrarte@polymera.bio
Uruguay

RED BIOTECH UY

Polymera

Biodegradable superabsorbents made by Antarctic bacteria



THE PROBLEM

More than four million tonnes of non-biodegradable, petroleum-derived superabsorbent polymers are produced annually. Manufacturers of hygiene products, food packaging and agricultural products need renewable, biodegradable alternatives that compete on cost and performance at industrial scale.

TECHNOLOGY

Polymera develops application-specific superabsorbents from a naturally superabsorbent polymer produced by fermentation using Antarctic bacteria. Its first material, for absorbent hygiene products, offers benchmark-comparable performance, twice the maximum absorption capacity and projected comparable costs. Bio-based, biodegradable and designed as a drop-in replacement, it can reduce diapers' plastic footprint by up to 50% and lower CO₂ emissions.

PRODUCT & MARKET

A portfolio of biodegradable superabsorbent polymers, with a first product for diapers, menstrual pads and incontinence products, and developments for fresh-food packaging and agriculture. The B2B model combines material sales and licensing to manufacturers.

WHAT WE ARE LOOKING FOR

Polymera seeks investment to scale production, commercially validate its polymers through hygiene-product pilots and develop materials for other markets. It seeks industrial partners with fermentation infrastructure and manufacturers to pilot the material on their production lines.



ANIMAL HEALTH

immunotherapy

antibodies

companion animals

KEY FACTS

Stage	Clinical stage
TRL	7
Founded	2021
Model	Licensing
Team	12-15

TEAM



Josefina Correa
CEO / co-founder



Emiliano Trias
CSO / co-founder



Luis Barbeito
CIO / co-founder

CONTACT

www.xeptiva.com
jcorrea@xeptiva.com
Montevideo, Uruguay

RED BIOTECH UY

Xeptiva Therapeutics

Immunotherapies for chronic diseases in companion animals



THE PROBLEM

Companion animals — dogs, cats, and horses — with chronic inflammatory conditions, such as osteoarthritis pain or atopic dermatitis, lack long-acting treatments; current therapies typically require frequent administration, are expensive, or cause unwanted side effects.

TECHNOLOGY

The platform uses injectable recombinant fusion immunogens to generate the animal's own antibodies against pain and inflammation mediators, with a prolonged effect. For Xep01, rNGFSP induced antibodies in mice, rabbits, horses and dogs; canine antibodies neutralized the target in cell assays, according to a peer-reviewed 2026 article. The company has produced its first industrial GMP batches and is conducting clinical efficacy trials for its two main products.

PRODUCT & MARKET

The pipeline covers five veterinary indications, led by Xep01 for chronic osteoarthritis pain and Xep02 for canine atopic dermatitis, plus equine and feline chronic pain and canine obesity. The company is moving toward a B2B2C model with veterinary pharma companies that register, manufacture and commercialise the products in Latin America, the United States and Europe.

WHAT WE ARE LOOKING FOR

Xeptiva is seeking capital to complete its clinical trials, secure regulatory registration and reach GMP manufacturing capacity, plus animal-health partners to support its expansion in Latin America, the United States and Europe.

